Innodem Neurosciences is committed to improving the effectiveness and quality of life and care of patients with neurological problems.
Innodem works with the pharmaceutical industry, leading medical professionals, and artificial intelligence experts to develop and promote Eye Movement Biomarkers (EMBs) & Gaze Mapping Biomarkers (GMBs) as important clinical assessment tools in the field of neurology. It is building a series of disease-specific tests embodied in an intuitive App that captures EMB & GMB data. The vision is that over time, while leveraging the latest advances in machine and deep learning, this EMB/GMB platform will assist users to accurately diagnose and monitor neurological disorders affecting eye-movements or cognition such as multiple sclerosis, Alzheirmer’s, Parkinson’s or related disorders, Frontotemporal dementia, Cancer-related cognitive impairment (Chemo Brain) and many others.
Company’s Keywords:
gaze tracking technology & mobile communication applications
<17
<
<2016